The Mcl-1 selective inhibitor VU661013 previously was shown to induce tumor cell killing in pre-clinical models of TNBC and acute myelogenous leukemia [26, 27], but has not yet been tested in models of ER+ breast cancer. The gene discussed is ESR1; the disease is acute myeloid leukemia.